v207771_ex99-1 -- Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing

Monday, January 10, 2011 BiopharmaWatch Research 1 min read

Key Takeaway: v207771_ex99-1 -- Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice

Cash runway

~11 mo

Medium dilution risk

Lead asset

SYN-010

Phase 2 · Irritable Bowel Syndrome With Constipation (IBS-C)

v207771_ex99-1 -- Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing